Back to Awarded Treatment Trials
Awarded Trial: 02-STN-008-2
Secondary Drug Intervention
Duration of Study Period for Each Subject
Amoxapine is an off-patent antidepressant that is thought to have antipsychotic properties at certain doses. Forty patients with schizophrenia were randomized to receive amoxapine (up to 250 mg/day) or risperidone (up to 5mg/day) for 6 weeks. Thirty-nine patients completed the study. Amoxapine was equivalent to risperidone for positive, negative and depressive symptoms. Amoxapine produced fewer extrapyramidal side effects and less elevation of prolactin than risperidone. Amoxapine may be an attractive alternative to newer antipsychotics because it is very in expensive.
Apiquian R, Fresan A, Ulloa RE, de la Fuente-Sandoval C, Herrera-Estrella M, Vazquez A, Nicolini H, Kapur S. Amoxapine as an atypical antipsychotic: a comparative study vs. risperidone. Neuropsychopharmacology. 2005 Dec;30(12):2236-44.
Centre for Addiction and Mental Health
250 College Street
City or Town
State or Province
Zip or Postal Code